Dancann Pharma

DanCann Pharma reported net sales of DKK 1.6 million in Q3 2025, a 37% increase from Q2 2025 but a 13% decrease from Q3 2024. The EBITDA improved to -DKK 1.0 million in Q3 2025, showing a 53% improvement from the previous quarter. Operating profit also improved, indicating progress in performance. Founder and CEO Jeppe Krog Rasmussen stepped down, with Chairman Carsten Trads as Interim CEO, and plans to appoint Peter Hauberg Søndergaard as the new CEO. The company will delist from the Spotlight Stock Market following shareholder approval, with plans for OTC trading to maintain transparency. DanCann Pharma remains focused on profitability and long-term value creation despite market volatility.

An extraordinary general meeting of DanCann Pharma A/S was held on October 21, 2025, in Denmark. The main agenda was to approve a proposal by the board of directors to apply for a voluntary delisting of the company's shares from the Spotlight Stock Market and to amend the company's articles of association accordingly. Attorney-at-law Michael Kristensen chaired the meeting, confirming that it was properly convened with 75,000 votes represented. The proposal required a 2/3 majority vote, which was achieved as it was unanimously adopted. The board plans to apply for delisting on January 7, 2026, with the last expected trading day on January 22, 2026. After delisting, the company's shares will be traded over-the-counter. The meeting concluded with the proposal's adoption.

DanCann Pharma is undergoing significant organizational changes and strategic realignment. The founder and CEO, Jeppe Krog Rasmussen, has resigned to pursue new challenges. Peter Hauberg Søndergaard, previously the CFO, is set to become the new CEO, focusing on guiding the company through a delisting process, improving operational efficiency, and executing a long-term growth plan called Maturity2028. The company plans to voluntarily delist from the Spotlight Stock Market due to high costs, administrative burdens, strategic realignment, reduced capital needs, and limited investor interest and liquidity. The delisting aims to allow DanCann Pharma to allocate resources more efficiently and secure capital through private channels. The Board believes these changes, including the leadership transition and delisting, are in the company's and shareholders' best interest, aiming for future profitability and sustainable growth.

DanCann Pharma A/S has scheduled an extraordinary general meeting for 21 October 2025 to discuss a proposal for voluntarily delisting the company's shares from the Spotlight Stock Market. The board of directors recommends this action due to high costs, administrative burdens, strategic realignment, and limited investor interest. Approval requires a two-thirds majority vote. If approved, the delisting application will be submitted on 7 January 2026, with the last trading day expected on 22 January 2026. Shareholders can attend the meeting in person, by proxy, or vote by post. The meeting will be conducted in English, and relevant documents are available on the company’s website.

DanCann Pharma A/S, a Danish biopharmaceutical company founded in 2018, plans to delist its shares from the Spotlight Stock Market. The decision follows a strategic shift since 2023, focusing on sourcing, import, and distribution, with reduced capital needs and a leaner organization. The board cites high costs and administrative burdens of remaining listed, limited investor interest, and better alignment with private equity markets as reasons for delisting. The proposal requires approval at an extraordinary general meeting and, if accepted, the application for delisting will be submitted on January 7, 2026, with the last trading day expected on January 22, 2026. Post-delisting, shares will trade over-the-counter, and the company will no longer adhere to certain public disclosure obligations but will continue operations and pursue strategic partnerships through private equity.

The financial summary for DanCann Pharma A/S for Q2-2025 shows a decrease in net sales and an increase in losses compared to the same period in 2024. The company experienced continued competitive pressure on its products Bedrocan® and Bediol®. Two new products, Bedrolite® and Bedrobinol®, were added to the portfolio, with their first contributions expected in Q3. The divestment of the production facility Biotech Pharm1 (BP1) is in its final stage. The Chairman of the Board, Carsten Trads, noted ongoing challenges but expressed optimism about future growth, particularly with the new product launches and strategic initiatives. The company's equity ratio remained stable at 0.66 compared to 0.32 in the previous year. DanCann Pharma A/S is a Danish biopharmaceutical company focused on cannabinoids, listed on the Spotlight Stock Market. The report includes forward-looking statements subject to risks and uncertainties.

DanCann Pharma A/S has entered into a DKK 2 million bridge loan agreement with a group of ten investors, including its largest shareholder, JEQ Capital AB. The loan is unsecured and does not involve related parties. It includes a 15% upfront fee and a 2% monthly fee. Lenders can convert their loan and fees into company shares at a price based on the recent average trading price of DKK 1.13 per share. The company can repay the loan at any time with a ten-day notice. If a capital raise occurs before repayment, lenders can convert their loan into underwriting commitments. DanCann Pharma A/S was founded in 2018, is focused on cannabinoids, and is listed on the Spotlight Stock Market. The company warns that forward-looking statements in the release are subject to risks and uncertainties that may affect actual results.

DanCann Pharma is in advanced negotiations to sell its production facility, BP1, to a European investment group focused on the energy sector. The group plans to use the facility for producing pharmaceutical-grade cannabis, targeting export markets like Germany. The conditional sales agreement is valued at EUR 1.25 million, with DanCann Pharma expected to net approximately EUR 0.75 million after excluding real estate, which is owned by a third party. The sale includes a bonus clause contingent on successful facility reapproval. DanCann Pharma has secured a bridge loan of DKK 2 million to maintain liquidity until the sale's initial payments are received. The company is also launching a new strategic plan, Maturity2028, focusing on positive cash flow, product expansion, potential mergers and acquisitions, and improved investor relations. The sales agreement remains non-binding, pending due diligence and alignment with the buyer's requirements, with exclusivity granted to the buyer for 60 days.